Vaccines Market

GlaxoSmithKline plc (UK) is the leading player in the global Vaccines Market

The global vaccines market is projected to reach USD 58.4 billion by 2024 from USD 41.7 billion in 2019, at a CAGR of 7.0% during the forecast period. The growth in this market is driven by the high prevalence of infectious diseases, increasing company initiatives to enhance vaccine R&D, growing government support for vaccine development, and the rising focus on immunization. However, the huge capital investments required for developing vaccines may restrain market growth.

The vaccines market is well established owing to the dominance of prominent market players, such as GlaxoSmithKline plc (UK), Pfizer, Inc. (US), Sanofi Pasteur (France), and Merck & Co., Inc. (US). Other prominent players in this market include CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E (India), Bharat Biotech (India), Sinovac Biotech Ltd (China), Incepta Vaccine Ltd. (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), and PT Bio Farma (Brazil).

To know about the assumptions considered for the study download the pdf brochure

GlaxoSmithKline (UK) dominated the vaccines market in 2018. The company offers an extensive range of vaccines for various diseases, such as polio, pneumococcal disease, DTP, hepatitis, influenza, HPV, meningococcal disease, rotavirus, and MMR. The company focuses on organic and inorganic growth strategies to maintain its position in the market and expand its global presence. For instance, in April 2019, GlaxoSmithKline invested USD 100 million in its manufacturing site in Hamilton, Montana (US), to expand the production capacity of vaccines. Moreover, in 2019, the company received the National Medical Products Administration (NMPA) approval for Shingrix for the prevention of shingles (herpes zoster) in people aged 50 years and over in China.

Merck & Co., Inc. (US) is another key player in the global vaccines market. The company has a strong presence in the Americas, the Asia Pacific, Europe, and the Middle East. The company focuses on increasing investments in R&D activities to enhance its product offerings. In this regard, in 2018, the company invested USD 8.0 billion in R&D activities. In December 2019, the company received the US FDA approval for ERVEBO, the first FDA-approved vaccine for the prevention of Ebola virus disease (EVD), caused by Zaire ebolavirus in individuals 18 years of age and older.

Related Reports:

Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, shingles, Rabies), Route (IM, SC, ID, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2024

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Report Code
PH 6528
RI Published ON
1/29/2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Vaccines Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved